Key result
eNOS intron 4a/b heterozygote genotype is linked to ~2.4-fold higher CAD risk.
Why the study?
Is the endothelial nitric oxide synthase (eNOS) intron 4a/b 27 VNTR polymorphism associated with the risk of coronary artery disease in the Thrace region of Turkey?
Case-Control (n=281)
Is the endothelial nitric oxide synthase (eNOS) intron 4a/b 27 VNTR polymorphism associated with the risk of coronary artery disease in the Thrace region of Turkey?
Answers are grounded in this paper and cite their sources.
Demonstrates a significant association between the eNOS intron 4a/b heterozygote genotype and increased risk of coronary artery disease as well as dyslipidemia in a Turkish population from the Thrace region.
Coronary artery disease (CAD) is one of the frequent cardiovascular mortality causes in the world. Common risk factors explain only about half the risk of CAD. The healthy familial predisposition to CAD, combined with advances in genetic analysis, has led to a number of studies in recent years making an effort to identify the genetic factors that influence the risk. The approach taken by most studies was to examine the association of naturally occurring genetic polymorphisms in candidate genes with risk of or severity of CAD. Endothelial nitric oxide synthase (eNOS) is important for vascular and tissue protection and is found in endothelial cells that encompass the entire vasculature, including the vessels in the heart. Nitric oxide (NO) is produced in a catabolic reaction in the endothelial cells, neurons, glia and macrophages by nitric oxide synthase (NOS) isoenzymes. eNOS is a subgroup of this family of enzymes that catalyses the production of nitric oxide (NO) from L-arginine and oxygen, which leads to vascular relaxation by activating the guanylate cyclase. This finally induces smooth muscle relaxation. The aim of this study was to investigate the allelic frequency and the genotypic distribution of the variable number of tandem repeat 27 (27 VNTR) gene polymorphism in intron 4 of the eNOS (eNOS 4a/b) gene in Thrace region, to compare CAD patients with appropriate healthy controls and to correlate the genetic findings with CAD subtypes. The study group included 281 (153 subjects with CAD and 128 controls) patients. The eNOS polymorphism was identified with a polymerase chain reaction. Genotypes were defined as aa, ab and bb according to the presence of a and b alleles. In this case-control study, we found that there was sensible correlation between eNOS gene intron 4a/b VNTR polymorphism and the risk of CAD in Thrace region of Turkey. However, there was no major difference for the genotype distribution and the allelic frequency among the CAD subtypes. Further studies on the interaction of such genes are needed to clarify the association between eNOS 4a/b polymorphism and CAD patients.
No takes yet. Share an insight, caveat, or question.
Sıvrı et al. (2014) conducted a case-control in Coronary artery disease (CAD) (n=281). eNOS intron 4a/b (27 VNTR) ab heterozygote genotype vs. eNOS intron 4a/b bb homozygote genotype was evaluated on Risk of developing coronary artery disease (CAD) (OR 2.376, 95% CI 1.329-4.248, p=0.004). The eNOS intron 4a/b heterozygote (ab) genotype was associated with an increased risk of coronary artery disease compared to Controls.
Synapse has enriched 10 related papers. Consider them for comparative context: